Terms: = Breast cancer AND BCR, FLJ16453, 613, ENSG00000186716, BCR1, D22S662, D22S11, CML, P11274, PHL, ALL AND Clinical Outcome
11 results:
1. African Ancestry-Associated Gene Expression Profiles in Triple-Negative breast cancer Underlie Altered Tumor Biology and clinical outcome in Women of African Descent.
Martini R; Delpe P; Chu TR; Arora K; Lord B; Verma A; Bedi D; Karanam B; Elhussin I; Chen Y; Gebregzabher E; Oppong JK; Adjei EK; Jibril Suleiman A; Awuah B; Muleta MB; Abebe E; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Chitale DA; Bensenhaver JM; Nathanson DS; Jackson L; Petersen LF; Proctor E; Stonaker B; Gyan KK; Gibbs LD; Monojlovic Z; Kittles RA; White J; Yates CC; Manne U; Gardner K; Mongan N; Cheng E; Ginter P; Hoda S; Elemento O; Robine N; Sboner A; Carpten JD; Newman L; Davis MB
Cancer Discov; 2022 Nov; 12(11):2530-2551. PubMed ID: 36121736
[TBL] [Abstract] [Full Text] [Related]
2. B cell-related gene signature and cancer immunotherapy response.
Lundberg A; Li B; Li R
Br J Cancer; 2022 Apr; 126(6):899-906. PubMed ID: 34921229
[TBL] [Abstract] [Full Text] [Related]
3. The potential utility of abbreviated breast MRI (FAST MRI) as a tool for breast cancer screening: a systematic review and meta-analysis.
Geach R; Jones LI; Harding SA; Marshall A; Taylor-Phillips S; McKeown-Keegan S; Dunn JA;
Clin Radiol; 2021 Feb; 76(2):154.e11-154.e22. PubMed ID: 33010932
[TBL] [Abstract] [Full Text] [Related]
4. Treatment of Metastatic or High-Risk Solid cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.
Nicolini A; Ferrari P; Morganti R; Carpi A
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795079
[TBL] [Abstract] [Full Text] [Related]
5. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
Shao X; Cai J; Zheng Y; Wang J; Feng J; Huang Y; Shi L; Chen Z; Guo Y; Wang X
Int J Clin Exp Pathol; 2015; 8(5):5309-17. PubMed ID: 26191232
[TBL] [Abstract] [Full Text] [Related]
6. Retrospective analysis of clinicopathological factors and outcome in breast cancer in young women in a tertiary care hospital in India.
Deshmukh SP; Mane AD; Zade BP; Sane SP
Indian J Cancer; 2014; 51(4):594-8. PubMed ID: 26842207
[TBL] [Abstract] [Full Text] [Related]
7. cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.
Lucas CM; Harris RJ; Giannoudis A; Copland M; Slupsky JR; Clark RE
Blood; 2011 Jun; 117(24):6660-8. PubMed ID: 21490338
[TBL] [Abstract] [Full Text] [Related]
8. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (bcrP) genes and clinical outcome in childhood acute lymphoblastic leukemia.
Kourti M; Vavatsi N; Gombakis N; Sidi V; Tzimagiorgis G; Papageorgiou T; Koliouskas D; Athanassiadou F
Int J Hematol; 2007 Aug; 86(2):166-73. PubMed ID: 17875533
[TBL] [Abstract] [Full Text] [Related]
9. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.
Elsheikh S; Green AR; Aleskandarany MA; Grainge M; Paish CE; Lambros MB; Reis-Filho JS; Ellis IO
Breast Cancer Res Treat; 2008 May; 109(2):325-35. PubMed ID: 17653856
[TBL] [Abstract] [Full Text] [Related]
10. breast cancer resistance protein (bcrP) in acute leukemia.
Plasschaert SL; Van Der Kolk DM; De Bont ES; Vellenga E; Kamps WA; De Vries EG
Leuk Lymphoma; 2004 Apr; 45(4):649-54. PubMed ID: 15160935
[TBL] [Abstract] [Full Text] [Related]
11. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
Allred DC; Clark GM; Tandon AK; Molina R; Tormey DC; Osborne CK; Gilchrist KW; Mansour EG; Abeloff M; Eudey L
J Clin Oncol; 1992 Apr; 10(4):599-605. PubMed ID: 1548522
[TBL] [Abstract] [Full Text] [Related]
